Atlas Trials

Epigenetic Reprogramming in Relapse/Refractory AML

Clinical trial NCT03263936 · COMPLETED

Trial details

NCT number
NCT03263936
Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Myelogenous Leukemia
Start date
2017-07-11
Primary completion
2020-07-09
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.